Pegmolesatide for the Treatment of Anemia in Non-dialysis-dependent Chronic Kidney Disease Patients: Post-hoc Analysis of a Phase 3 Trial

Xueqing Yu¹, Jianteng Xie¹, Aicheng Yang², Hongyu Qiu³, Xiaomei Peng⁴, Wanhong Lu⁵, Qinkai Chen⁶, Aimin Zhong⁷, Shuifu Tang⁸, Zhizhen Hu⁹, Ping Li⁹

¹Guangdong Provincial People's Hospital. ²Affiliated Jiangmen Traditional Chinese Medicine Hospital of Jinan University. ³West China Hospital of Sichuan University. ⁴The People's Hospital of Guangxi Zhuang Autonomous Region. ⁸The First Affiliated Hospital of Xi'an Jiaotong University. ⁶First Affiliated Hospital of Nanchang University. ⁷Jiangxi Provincial People's Hospital. ⁸Guangzhou University of Traditional Chinese Medicine First Affiliated Hospital. ⁹Jiangsu Hansoh Pharmaceutical Co., Ltd.

Introduction

Pegmolesatide, a novel long-acting pegylated erythropoietin mimetic peptide (EMP), is approved in China for treating anemia in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients. A randomized, multicenter, open-label, active-controlled, non-inferiority phase 3 study (Figure 1) demonstrated comparable efficacy and safety of pegmolesatide to epoetin alfa in managing renal anemia in NDD-CKD patients.

Objective

To explore further benefits of pegmolesatide in NDD-CKD patients with anemia.

Methods

- A total of 175 NDD-CKD patients without erythropoiesisstimulating treatment were randomized (2:1) to receive pegmolesatide or epoetin alfa for 52 weeks.
- This post-hoc analysis included subgroup-assessments of hemoglobin (Hb) level change from baseline to evaluation period, as well as evaluation of iron therapy, serum ferritin (SF) and transferrin saturation (TSAT).




Figure 1. Study Design

Results

- Pegmolesatide resulted in a greater increase in Hb from baseline to evaluation period compared to epoetin alfa (*P*=0.0163, Figure 2).
- Better efficacy was observed in patients ≥65 years old, with baseline eGFR <15 mL/min/1.73 m² or SF <200 ng/mL.
- Numerically less patients in pegmolesatide group required iron therapy (41.7% vs. 56.9%), or folic acid and vitamin B12 (24.3% vs. 29.3%) compared to epoetin alfa group.
- Those who received pegmolesatide were more likely to have a smaller reduction in SF and TSAT over 52 weeks (Figure 3).

Conclusion


Pegmolesatide is non-inferior in increasing Hb level compared to epoetin alfa, and may optimize iron supplements and utilizations in NDD-CKD patients.

Figure 2. Forest Plot in Subgroup Analysis of the Change in Hemoglobin Level from Baseline to the Evaluation Period (FAS)

742, 2.098) 073, 2.648) 280, 1.703) 704, 2.101) 571, 2.432) 568, 2.182) 738, 2.172)	1.542 (1.291, 1.793) 1.840 (1.405, 2.274) 1.237 (0.957, 1.517) 1.615 (1.340, 1.890) 1.134 (0.472, 1.796) 1.433 (1.039, 1.828) 1.643 (1.313, 1.973)	+ + + + +	0.378 (0.070, 0.686) 0.521 (-0.002, 1.044) 0.255 (-0.097, 0.606) 0.288 (-0.053, 0.628) 0.868 (0.072, 1.663) 0.442 (-0.059, 0.942)	0.0163 0.0508 0.1533 0.0969 0.0337 0.0831
280, 1.703) 704, 2.101) 571, 2.432) 568, 2.182)	1.237 (0.957, 1.517) 1.615 (1.340, 1.890) 1.134 (0.472, 1.796) 1.433 (1.039, 1.828)	(+I	0.255 (-0.097, 0.606) 0.288 (-0.053, 0.628) 0.868 (0.072, 1.663)	0.1533 0.0969 0.0337
280, 1.703) 704, 2.101) 571, 2.432) 568, 2.182)	1.237 (0.957, 1.517) 1.615 (1.340, 1.890) 1.134 (0.472, 1.796) 1.433 (1.039, 1.828)	(+I	0.255 (-0.097, 0.606) 0.288 (-0.053, 0.628) 0.868 (0.072, 1.663)	0.1533 0.0969 0.0337
704, 2.101) 571, 2.432) 568, 2.182)	1.615 (1.340, 1.890) 1.134 (0.472, 1.796) 1.433 (1.039, 1.828)		0.288 (-0.053, 0.628) 0.868 (0.072, 1.663)	0.0969 0.0337
571, 2.432) 568, 2.182)	1.134 (0.472, 1.796) 1.433 (1.039, 1.828)	┝┥ ┝╺┤	0.868 (0.072, 1.663)	0.0337
571, 2.432) 568, 2.182)	1.134 (0.472, 1.796) 1.433 (1.039, 1.828)	┝┥ ┝╼┤ ┝┙	0.868 (0.072, 1.663)	0.0337
568, 2.182)	1.433 (1.039, 1.828)	++ +		
		 ≁ 	0.442 (-0.059, 0.942)	0.0921
		+ +	0.442 (-0.059, 0.942)	0.0921
738, 2.172)	1.643 (1.313, 1.973)	لمأ		0.0831
		1-1	0.312 (-0.083, 0.708)	0.1204
912, 2.448)	1.531 (1.144, 1.918)	H+H	0.649 (0.178, 1.120)	0.0076
424, 2.026)	1.536 (1.157, 1.915)	l '+ 1	0.189 (-0.296, 0.674)	0.4382
365, 2.454)	1.567 (0.815, 2.319)	⊢⊶⊷⊣	0.343 (-0.588, 1.273)	0.4562
716, 2.078)	2.051 (-0.150, 4.251)	⊢ • <u>+</u> −1	-0.654 (-2.967, 1.660)	0.5330
620, 2.169)	1.411 (1.023, 1.800)	I +I	0.483 (0.007, 0.958)	0.0468
702, 2.168)	1.626 (1.294, 1.957)	/+	0.309 (-0.096, 0.714)	0.1339
946, 4.512)	2.313 (0.267, 4.359)	⊢ +•−−1	0.916 (-1.519, 3.351)	0.3552
201, 1.799)	1.378 (0.993, 1.763)	H+-1	0.123 (-0.366, 0.611)	0.6187
962, 2.444)	1.635 (1.278, 1.992)	 +-	0.568 (0.136, 1.000)	0.0108
430, 2.280)	1.952 (1.236, 2.668)	⊢+-1	-0.097 (-0.934, 0.740)	0.8094
		-3 -2 -1 0 1 2 3		
	avore Enoctin alfa		- Favors Permolesa	tide
	962, 2.444) 430, 2.280)	962, 2.444) 1.635 (1.278, 1.992)	962, 2 444) 1 635 (1 278, 1 992) 430, 2 280) 1 952 (1 236, 2 668) -3 -2 -1 0 1 2 3	962, 2 444) 1 635 (1 278, 1 992) 430, 2 280) 1 952 (1 236, 2 668) -0 097 (-0 934, 0 740) -3 -2 -1 0 1 2 3

The *P* values for the difference between the two groups were estimated based on Analysis of Covariance model (ANCOVA), with the mean change in Hb level from baseline to the efficacy evaluation period as the dependent variable, treatment group as the explanatory variable and baseline Hb values as the covariate.

Figure 3. Changes in Iron Usage, Serum Ferritin, and Transferrin Saturation (TSAT) Levels (FAS)



Financial Disclosures

None

References

- Xie J, Yang A, Qiu H, et al. Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD. Kidney International Reports, 2024.
- 2. Zhang P, Jiang Y, Xu C, et al. Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial. *EClinicalMedicine*. 2023;65:102273.